台湾浩鼎生技宣布停止其抗体OBI 888的1/2期研究,以专注于其他优先癌症项目
台湾台北, July 06, 2022 (GLOBE NEWSWIRE) — 台湾生物制药公司浩鼎生技(OBI Pharma,台北证券交易所代码:4174)今天宣布,在完成公司的调查场点招募后,停止OBI 888(一种Globo H抗体)的1/2期研究*。
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.